


Author's Accepted Manuscript

Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data

Maria Hoeltzenbein, Evelin Beck, Richa Rajwanshi, Carina Gøtestam Skorpen, Erhan Berber, Christof Schaefer, Monika Østensen



PII: S0049-0172(16)30056-7
DOI: <http://dx.doi.org/10.1016/j.semarthrit.2016.05.004>
Reference: YSARH51054

To appear in: *Seminars in Arthritis and Rheumatism*

Received date: 5 January 2016
Revised date: 15 April 2016
Accepted date: 20 May 2016

Cite this article as: Maria Hoeltzenbein, Evelin Beck, Richa Rajwanshi, Carina Gøtestam Skorpen, Erhan Berber, Christof Schaefer and Monika Østensen, Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data, *Seminars in Arthritis and Rheumatism*, <http://dx.doi.org/10.1016/j.semarthrit.2016.05.004>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Tocilizumab use in pregnancy: Analysis of a Global Safety Database including data from clinical trials and post-marketing data

Maria Hoeltzenbein^{1*}, Evelin Beck^{1*}, Richa Rajwanshi², Carina Gøtestam Skorpen^{3,4,5}, Erhan Berber², Christof Schaefer¹, Monika Østensen^{3,4}

* shared first authorship

¹Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy, Charité - Universitätsmedizin Berlin, Germany

²Genentech, Inc., A Member of the Roche Group, South San Francisco, California, United States

³National Service for Pregnancy and Rheumatic Diseases, Department of Rheumatology, Trondheim University Hospital, Trondheim, Norway

⁴Dept of Neuroscience, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

⁵Dept of Rheumatology, Ålesund Hospital, Ålesund, Norway

Address for correspondence

Dr. med. Maria Hoeltzenbein

Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy

Charité - Universitätsmedizin Berlin

Augustenburger Platz 1

D - 13353 Berlin

Germany

Tel.: +49 (0) 30 450 525 702

Fax: +49 (0) 30 450 525 902

maria.hoeltzenbein@charite.de

Abbreviations:

TCZ Tocilizumab, IL-6 interleukin 6, DMARD disease-modifying antirheumatic drugs, RA rheumatoid arthritis, TNF tumor necrosis factor, MTX methotrexate, LMP last menstrual period, ETOP elective termination of pregnancy,

Download English Version:

<https://daneshyari.com/en/article/5584012>

Download Persian Version:

<https://daneshyari.com/article/5584012>

[Daneshyari.com](https://daneshyari.com)